Arrowstreet Capital
TBPH icon

Arrowstreet Capital’s Theravance Biopharma TBPH Stock Holding History

Arrowstreet Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.32M Sell
327,546
-635,711
-66% -$11.2M ﹤0.01% 1143
2025
Q4 		$18M Buy
963,257
+236,474
+33% +$3.92M 0.01% 769
2025
Q3 		$10.6M Buy
+726,783
New +$9.18M 0.01% 940
2025
Q2 		– Sell
-221,469
Closed -$1.98M – 2084
2025
Q1 		$1.98M Buy
+221,469
New +$2.06M ﹤0.01% 1300
2015
Q1 		– Sell
-18,431
Closed -$275K – 1220
2014
Q4 		$275K Buy
+18,431
New +$321K ﹤0.01% 1147

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's TBPH Position: Q1 2026 in Review

Arrowstreet Capital reduced its Theravance Biopharma (TBPH) stake by 66% in Q1 2026, selling an estimated $11.2M and leaving 327,546 shares worth $5.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1143.

Arrowstreet Capital first reported a position in TBPH in Q4 2014 and has held it in 5 quarters since. The position peaked at $18M in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Arrowstreet Capital held 327,546 shares of Theravance Biopharma worth $5.32M as of Q1 2026.
  • Arrowstreet Capital sold 635,711 Theravance Biopharma shares in Q1 2026, an estimated $11.2M.
  • Theravance Biopharma made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1143 holding.
  • Arrowstreet Capital first reported a position in Theravance Biopharma in Q4 2014 and has held it in 5 quarters since.
  • Arrowstreet Capital's Theravance Biopharma position peaked at $18M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.